Topical SGX302 for Mild-to-Moderate Psoriasis

Launched by SOLIGENIX · Jun 28, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SGX302, which is a topical ointment made with hypericin, used alongside visible light therapy. The aim is to see if this treatment can help improve skin lesions in people with mild-to-moderate psoriasis, a skin condition that causes red, flaky patches. The study will last for 18 weeks, and researchers are looking for participants who have been diagnosed with plaque psoriasis for at least six months and have affected areas on their body that are suitable for topical treatment.

To be eligible for this trial, participants should have mild to moderate psoriasis affecting 2-30% of their body, including the trunk and limbs. They must not have used other psoriasis treatments within a certain timeframe before starting the study. If you decide to join, you can expect regular visits to the clinic for treatment and monitoring of your skin condition. This trial is currently recruiting participants of all genders, aged between 18 and 65. If you're interested in exploring a new treatment option, this might be an opportunity to consider!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application.
• • Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).
• • Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.
• Exclusion Criteria:
• • Use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study.
• • Received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study.
• • Received systemic psoriasis therapy within 4 weeks prior to the beginning of the study.
• • Received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.